COGS reduction efforts.

ir_statement / Sep 17, 2026 / receipt

Significant step up in clinical trial spend focused on Signatera.

ir_statement / Sep 17, 2026 / receipt

Holding guide constant; commercial investments scaling efficiently

ir_statement / Sep 17, 2026 / receipt

Raising 2026 annual revenue guidance

ir_statement / Sep 17, 2026 / receipt

>1.04M total tests processed in Q2 2026 vs 853K in Q2 2025; year-over-year growth of >22%.

ir_statement / Sep 17, 2026 / receipt

Raising 2026 outlook, $100M increase in revenue at the midpoint.

ir_statement / Sep 17, 2026 / receipt

Revenue of $753M in Q2 2026 vs $547M in Q2 2025; year-over-year growth of ~38%.

ir_statement / Sep 17, 2026 / receipt

Continued sequential step up in ASPs.

ir_statement / Sep 17, 2026 / receipt

Efficient Signatera COGS.

ir_statement / Sep 17, 2026 / receipt

Medical Science Liaison | {"ats": "greenhouse", "city": null, "state": null, "job_id": "6193494004", "remote": true, "category": "other", "function": "clinical", "location": "US Remote", "job_title":

company_statement / Sep 16, 2026 / receipt

Natera expects the Women’s Health business to reach cash flow breakeven in 2021

ir_statement / Sep 16, 2026 / receipt

Raising 2021 Annual guidance

ir_statement / Sep 16, 2026 / receipt